Your browser doesn't support javascript.
loading
Research progress of allogeneic stem cell transplantation in multiple myeloma patients / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma ; (12): 311-314, 2014.
Artículo en Chino | WPRIM | ID: wpr-475703
ABSTRACT
Allogeneic stem cell transplantation (allo-HSCT) is probably the only treatment for multiple myeloma (MM) with a curative potential.However,the application of allo-HSCT is limited by the high transplant-related mortality (TRM).Although the introduction of reduced intensity conditioning (RIC) has lowered the TRM associated with myeloablative conditioning,there is no improvement in survival of allo-RIC compared to autologous stem cell transplantation (auto-HSCT).New strategies are discussed with the aim of lowering transplant toxicity and boosting the graft-versus-myeloma effect,and these are urgently needed to make allo-RIC safer and more effective for myeloma patients.In this review,results from studies of allo-HSCT in MM are presented.

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Journal of Leukemia & Lymphoma Año: 2014 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Journal of Leukemia & Lymphoma Año: 2014 Tipo del documento: Artículo